Astragalin attenuates diabetic cataracts via inhibiting aldose reductase activity in rats  

作　　者：Na Wang Deepika Singh Qiong Wu 

机构地区：[1]Department of Ophthalmology,Shaanxi Eye Hospital,Xi’an People’s Hospital(Xi’an Fourth Hospital),Affiliated People’s Hospital of Northwest University,Xi’an 710004,Shaanxi Province,China [2]Department of Pharmaceutical Sciences,Sam Higginbottom University of Agriculture,Technology and Sciences,Prayagraj 211007,India

出　　处：《International Journal of Ophthalmology(English edition)》2023年第8期1186-1195,共10页国际眼科杂志（英文版）

摘　　要：AIM:To investigate the aldose reductase(AR)inhibition capacity of astragalin(AST)against streptozoticin-induced diabetic cataracts(DCs)in rats.METHODS:Ex vivo investigations were conducted by treating the lens of a goat placed for 72h in artificial aqueous humor(AAH)of pH 7.8 at room temperature with cataract-causing substance(55 mmol/L of galactose)and in vivo studies were performed on rats via induction with streptozotocin.AST was administered at different dose levels and scrutinize for DC activity.RESULTS:In diabetic rats,AST improved the body weight,blood insulin,and glucose as well as the levels of galactitol in a dose-dependent way,other biochemical parameters i.e.inflammatory mediators and cytokines,and also suppress AR activity.The level of the antioxidant parameters such as superoxide dismutase(SOD),catalase(CAT),and glutathione(GSH)activity were also altered on a diabetic lens after the administration of the AST.CONCLUSION:AST protects against lens opacification to avoid cataracts and polyols formation,indicating that it could be used as a potential therapeutic agent for diabetes.

关 键 词：ASTRAGALIN diabetic cataract LENS OPACIFICATION aldose reductase rats 

分 类 号：R285.5[医药卫生—中药学]